Matthew Sykes
Stock Analyst at Goldman Sachs
(3.78)
# 742
Out of 4,996 analysts
205
Total ratings
50%
Success rate
8.49%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $8.68 | -42.40% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $3.40 | -11.76% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $11.72 | -44.54% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $31.04 | +44.97% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $7.70 | +3.90% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $26.91 | +78.37% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $15.82 | +7.46% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $163.79 | -2.31% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.93 | +26.10% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $84.06 | +48.70% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $11.84 | +18.24% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $184.84 | +29.84% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $14.94 | +74.03% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $148.56 | +14.43% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $60.03 | -6.71% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $117.21 | -31.75% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.21 | +23.97% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $162.97 | +16.59% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.83 | +111.66% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.82 | +50.71% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $33.44 | +10.65% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $53.57 | +21.34% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $179.56 | +39.23% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.19 | +362.43% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,204.43 | +7.93% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $11.50 | +4.35% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $464.24 | +37.86% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $123.39 | +17.51% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $43.90 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $8.68
Upside: -42.40%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $3.40
Upside: -11.76%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $11.72
Upside: -44.54%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $31.04
Upside: +44.97%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $7.70
Upside: +3.90%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $26.91
Upside: +78.37%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $15.82
Upside: +7.46%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $163.79
Upside: -2.31%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.93
Upside: +26.10%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $84.06
Upside: +48.70%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $11.84
Upside: +18.24%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $184.84
Upside: +29.84%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $14.94
Upside: +74.03%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $148.56
Upside: +14.43%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $60.03
Upside: -6.71%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $117.21
Upside: -31.75%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.21
Upside: +23.97%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $162.97
Upside: +16.59%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.83
Upside: +111.66%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.82
Upside: +50.71%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $33.44
Upside: +10.65%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $53.57
Upside: +21.34%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $179.56
Upside: +39.23%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.19
Upside: +362.43%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,204.43
Upside: +7.93%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $11.50
Upside: +4.35%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $464.24
Upside: +37.86%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $123.39
Upside: +17.51%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $43.90
Upside: -